Search results

Showing 1 - 10 of 11 results

1 2
next

The Big 2007 MT Quiz

Roll up roll up! Today's your last chance to enter MT's first ever end-of-year prize quiz on the business highlights of 2007...

Boots pays £1.5bn dividend to new owners

The credit crunch has made the last few months a bit of a struggle for the big private equity firms, but at least one seems to have played its cards right. After buying Alliance Boots this summer, KKR and partner Stefano Pessina not only managed to raise all the debt they needed; they also paid themselves...

Health and safety in 'not killjoys' shock

The incoming president of the Institution of Occupational Safety and Health, Europe’s largest industry body, has raged against all those who have ever criticised his profession as 'bureaucratic busy-bodies, red tape robots or tick box Tonys'. So that’s presumably just about all of us, then…

More flexible parenting

MT has always championed flexible working – if done right, it can lead to a happier, better-motivated and more productive workforce. But the government’s plans to extend this right, announced yesterday in the Queen’s Speech, will have expensive implications for British businesses – so however noble...

A bitter pill for Glaxo

GlaxoSmithKline may have finally resolved its long-running succession problem, but new chief executive Andrew Witty will have some problems to address when he takes over next May.

EU opens its doors with blue card scheme

Hiring qualified non-Europeans to plug your skill gaps is about to get easier – unless you’re in Britain, that is.

Witty gets the nod at GSK

One of the longest-running succession battles in the corporate world came to an end on Monday, after unfancied Brit Andrew Witty was appointed chief executive of GlaxoSmithKline.

Another one bites the dust

Jaguar, British Steel, Austin, Rover… Now the once grand ICI can join the ever-lengthening list of British industrial giants being sold off to foreign interests. The chemicals company has agreed to be taken over by its Dutch rival Akzo Nobel, in a deal valuing it at £8bn. ICI may have become a shadow...

It's kicking off in the battle for Boots

'Trust Boots' goes the slogan. Now that the chemist has become the centre of a £10bn-plus private equity bidding war, a lot of people are going to find that much more difficult to do. After all, private equity hardly wins praise for its openness, and the target here is a 158-year-old staple of the high...

Crash Course: Brainstorming

Your business needs some bright ideas. Everyone's got their head down for much of the time and the spark of creativity has turned into a damp squib. Maybe it's time to try a spot of brainstorming.

Sort results by: date | relevance

Search filters:

By Date

  • 2007 Remove filter

By Industry Sector

  • Pharmaceuticals & Biotechnology Remove filter

Click remove filters icon to remove filters

Clear this search

Add Search Filters:

By Publication

By Article Type

1 2
next

Additional Information